FIELDING THE FUTURE
are serving as a road map for vaccine and therapy development. By better under- standing that specific portion of the virus through images like those WRAIR has developed, scientists can better determine how to prevent it from infecting people.
Te command’s partnerships with indus- try and academia are bolstering efforts during this time. WRAIR, for exam- ple, is actively working with the National Institutes of Health and industry part- ners to evaluate promising vaccines in various stages of development. WRAIR is also collaborating with the Army Public Health Center on a pilot project that will include blood tests for COVID-19 expo- sure in Army recruit training, to reduce the threat of exposure and impact on recruits while in training.
USAMRDC’s U.S. Army Medical Mate- riel Development Activity (USAMMDA) recently entered into a cooperative research and development agreement with Gilead Sciences Inc. to use the investigational drug remdesivir to treat active-duty Army personnel exposed to COVID-19. Te drug was shipped to 13 military treat- ment facilities. An investigational drug
MEET THE PRESS
Secretary of the Army Ryan D. McCarthy listens to a question from a reporter during a news conference at USAMRIID in March. McCarthy, Army Chief of Staff Gen. James C. McConville, right, and Sergeant Major of the Army Michael A. Grinston visited USAMRIID to understand how the Army medical research and development community is responding to the COVID-19 pandemic. (Photo by Erin Bolling, USAMRDC Public Affairs)
face to face was really helpful to me in understanding what they’re doing.
“The chance to talk to the doctors ”
is a substance that has been tested in the laboratory and has been approved by the FDA for testing in people.
Additionally, USAMMDA contributed medical materiel expertise to the virus response effort following the late March deployment announcement of a handful of hospital centers and combat support hospitals. Te USAMMDA Warfighter Deployed Medical Systems (WDMS) team has been tasked with filling shortages for the deploying units by surveying current equipment stock, cutting stock transfer orders to facilitate delivery of key materi- als and coordinating with a slew of other agencies, including U.S. Army Sustain- ment Command and U.S. Army Materiel Command, to ensure that deploying units have the equipment required to perform
their missions. “We have been working on ensuring any shortages in equipment for the mission are top priority to fulfill,” says Lindsay Longobardi, deputy proj- ect manager for WDMS. “Our team has exercised multiple contracting actions to ensure critical care medical devices [are] shipped to the units [and] on the ground in as little as 24 hours.”
Several other Army laboratories are lend- ing their expertise in the fight against COVID-19. Te U.S. Army Aeromed- ical Research Laboratory performed a rapid-response evaluation of aircrew performance while wearing an N-95 mask and various models of cloth masks to assess the effects of wearing the mask for speech intelligibility, usability, work- load, situational awareness and comfort,
https://asc.ar my.mil
61
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172
